Nanjing Miracle Biotechnology Co., Ltd.

Researchers are testing a new cell therapy called CHT105 in up to 24 adults with relapsed or refractory autoimmune diseases, including immune thrombocytopenia (ITP). CHT105 uses donor-derived CAR-T cells engineered to target two markers, CD19 and CD70, on immune cells. The goal i…

Researchers are testing an experimental cell therapy called CHT101 in adults with T-cell or B-cell blood cancers that have returned or stopped responding to treatment. CHT101 uses donor-derived T cells engineered to recognize CD70, a marker found on these cancer cells. The phase …

Researchers are testing CHT101, an experimental CAR-T cell therapy made from donor cells, in adults with T-cell or B-cell blood cancers that have come back or stopped responding to treatment. The therapy targets CD70, a marker found on these cancer cells. The Phase I trial aims t…